Physician profile
Raphael Darvish
NPI 1245457811
$2,853.90
in general payments reported to CMS, 2019-2025
17 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $181 · 2021: $379 · 2022: $148 · 2023: $456 · 2024: $285 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58.00 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58.00 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $605.23 | 2019-2022 | |
| Abbvie INC. | $450.37 | 2023-2025 | Botox |
| Revance Therapeutics, INC. | $308.82 | 2025 | Daxxify |
| Viiv Healthcare Company | $288.63 | 2020-2025 | Apretude |
| Merz North America, INC. | $285.75 | 2021-2025 | Xeomin |
| Gilead Sciences, INC. | $254.26 | 2019-2022 | |
| Genentech USA, INC. | $148.38 | 2019-2021 | |
| Amgen INC. | $125.00 | 2021 | |
| Galderma Laboratories, L.P. | $95.94 | 2019-2024 | |
| Medline Industries Lp | $91.92 | 2023 | |
| Lilly USA, LLC | $58.35 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $51.36 | 2024-2025 | Airsupra |
| Hologic Sales and Service, LLC | $24.71 | 2023 | Aptima |
| Nabriva Therapeutics, Plc | $20.14 | 2020 | |
| Glaxosmithkline, LLC. | $19.37 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $16.07 | 2023 | Rs 4i Plus Sequential Stimulator |
| Electronic Waveform Lab, INC. | $9.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Darvish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.